{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hypertension+Stage+1&page=2", "query": { "condition": "Hypertension Stage 1", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hypertension+Stage+1&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-07-24T14:54:39.978Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00281593", "title": "Telmisartan (Micardis) and Ramipril (Altace) - Factorial Design Study for the Treatment of Hypertension", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypertension" ], "interventions": [ { "name": "Telmisartan", "type": "DRUG" }, { "name": "Ramipril", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1354, "start_date": "2006-04", "completion_date": null, "has_results": false, "last_update_posted_date": "2017-12-28", "last_synced_at": "2026-07-24T14:54:39.978Z", "location_count": 70, "location_summary": "Glendale, Arizona • Tempe, Arizona • Tucson, Arizona + 58 more", "locations": [ { "city": "Glendale", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Buena Park", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00281593" }, { "nct_id": "NCT00328666", "title": "The Penn Lifestyle Modification and Blood Pressure Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Hypertension" ], "interventions": [ { "name": "Iyengar yoga", "type": "BEHAVIORAL" }, { "name": "Enhanced nutritional care classes", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 60, "start_date": "2005-02", "completion_date": "2007-01", "has_results": false, "last_update_posted_date": "2015-11-25", "last_synced_at": "2026-07-24T14:54:39.978Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00328666" }, { "nct_id": "NCT03626688", "title": "A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "PAH", "Pulmonary Hypertension", "Pulmonary Arterial Hypertension", "Hypertension", "Connective Tissue Diseases", "Familial Primary Pulmonary Hypertension", "Vascular Diseases", "Cardiovascular Diseases", "Hypertension, Pulmonary", "Lung Diseases", "Respiratory Tract Disease" ], "interventions": [ { "name": "Ralinepag", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "United Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 687, "start_date": "2019-01-24", "completion_date": "2025-12-31", "has_results": false, "last_update_posted_date": "2026-06-16", "last_synced_at": "2026-07-24T14:54:39.978Z", "location_count": 68, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 50 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Loma Linda", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03626688" }, { "nct_id": "NCT00638742", "title": "A Phase 1, Open-Label Study of Latanoprost Acid Plasma Concentrations in Pediatric and Adult Glaucoma Patients Treated With Latanoprost.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glaucoma", "Ocular Hypertension" ], "interventions": [ { "name": "latanoprost", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Years", "maximum_age": null, "sex": "ALL", "summary": "0 Years and older" }, "enrollment_count": 47, "start_date": "2008-05", "completion_date": "2009-03", "has_results": false, "last_update_posted_date": "2021-02-02", "last_synced_at": "2026-07-24T14:54:39.978Z", "location_count": 6, "location_summary": "Artesia, California • Atlanta, Georgia • North Dartmouth, Massachusetts + 2 more", "locations": [ { "city": "Artesia", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "North Dartmouth", "state": "Massachusetts" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00638742" }, { "nct_id": "NCT04688632", "title": "Thorough QT Study to Evaluate Ampreloxetine in Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Symptomatic Neurogenic Orthostatic Hypertension", "nOH" ], "interventions": [ { "name": "Ampreloxetine ", "type": "DRUG" }, { "name": "Ampreloxetine ", "type": "DRUG" }, { "name": "Ampreloxetine Placebo", "type": "DRUG" }, { "name": "Moxifloxacin", "type": "DRUG" }, { "name": "Moxifloxacin Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Theravance Biopharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 72, "start_date": "2021-01-18", "completion_date": "2021-03-26", "has_results": false, "last_update_posted_date": "2021-04-20", "last_synced_at": "2026-07-24T14:54:39.978Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04688632" }, { "nct_id": "NCT03488550", "title": "Single-dose Study of ANX007 in Participants With Primary Open-angle Glaucoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Open-angle Glaucoma" ], "interventions": [ { "name": "ANX007", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Annexon, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2018-03-23", "completion_date": "2018-08-03", "has_results": false, "last_update_posted_date": "2020-08-20", "last_synced_at": "2026-07-24T14:54:39.978Z", "location_count": 1, "location_summary": "Newport Beach, California", "locations": [ { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03488550" }, { "nct_id": "NCT07252037", "title": "Dietary Guidelines for Americans-Ultra Processed Study", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Overweight , Obesity", "Class I Obesity" ], "interventions": [ { "name": "Low-processed DGA Diet", "type": "OTHER" }, { "name": "Ultra-processed DGA Diet", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "USDA Grand Forks Human Nutrition Research Center", "sponsor_class": "FED", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 79, "start_date": "2026-12", "completion_date": "2029-12", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-07-24T14:54:39.978Z", "location_count": 1, "location_summary": "Grand Forks, North Dakota", "locations": [ { "city": "Grand Forks", "state": "North Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT07252037" }, { "nct_id": "NCT05961384", "title": "Phase 1 Study to Determine the Metabolism and Clearance of Baxdrostat", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hypertension" ], "interventions": [ { "name": "baxdrostat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "MALE", "summary": "18 Years to 55 Years · Male only" }, "enrollment_count": 8, "start_date": "2021-11-18", "completion_date": "2022-01-15", "has_results": false, "last_update_posted_date": "2023-08-15", "last_synced_at": "2026-07-24T14:54:39.978Z", "location_count": 1, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT05961384" }, { "nct_id": "NCT05989581", "title": "Chronic Hypertension and Pregnancy 2 (CHAP2) Pilot Project", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hypertension in Pregnancy" ], "interventions": [ { "name": "Labetalol or Nifedipine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "14 Years", "maximum_age": "89 Years", "sex": "FEMALE", "summary": "14 Years to 89 Years · Female only" }, "enrollment_count": 74, "start_date": "2024-04-24", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-04-09", "last_synced_at": "2026-07-24T14:54:39.978Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT05989581" }, { "nct_id": "NCT03464864", "title": "Pharmacokinetics, Safety and Tolerability of Treprostinil Inhalation Powder in Healthy Normal Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pulmonary Arterial Hypertension" ], "interventions": [ { "name": "Treprostinil Inhalation Powder", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mannkind Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 36, "start_date": "2018-03-09", "completion_date": "2018-06-05", "has_results": false, "last_update_posted_date": "2018-10-30", "last_synced_at": "2026-07-24T14:54:39.978Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03464864" } ] }